שווי חברה לרווח נקי Protagenic Therapeutics, Inc. (PTIX)

This chart of the P/E ratio history for Protagenic Therapeutics (PTIX) currently shows a level of -0.20. Protagenic Therapeutics is implementing software robots to process CNS data arrays and is testing automated screening stations. The business relies on bioinformatics IT platforms to create synthetic neuropeptides, eliminating routine tasks for personnel. The development of treatments for anxiety and depression is being conducted in collaboration with leading neurobiological centers.

Protagenic Therapeutics (PTIX) develops neuroactive peptides for the treatment of depression and anxiety disorders. The P/E ratio relates the current market value of a share to the net profit per share. By analyzing the historical P/E dynamics of Protagenic Therapeutics (PTIX), an investor determines the payback period of the investment. This marker measures market expectations regarding the issuer's future cash flows. Low values may signal undervaluation or fundamental business risks.